Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.
暂无分享,去创建一个
Andrea Califano | Stephen S Roberts | Ryma Benayed | Marc Ladanyi | Elli Papaemmanuil | Audrey Mauguen | Gunes Gundem | David M Hyman | Hongxu Ding | Andrew L Kung | R. Darnell | M. Ladanyi | A. Califano | E. Papaemmanuil | G. Gundem | N. Shukla | R. Benayed | D. Hyman | Hongxu Ding | A. Kung | A. Jungbluth | I. Gushterova | L. Spraggon | Daoqi You | L. Smyth | S. Roberts | A. Mauguen | F. D. Dela Cruz | Daniel Diolaiti | Lee Spraggon | Achim A Jungbluth | Daoqi You | Emily K Slotkin | Jennifer J. Clark | M. Levine | Daniel Diolaiti | E. Slotkin | Jennifer J Clark | Venkata D Yellapantula | Neerav N Shukla | Filemon S Dela Cruz | Max F Levine | Peilin Ma | Sagarika Pachhal | Glorymar Ibanez Sanchez | Lillian M Smyth | Irena Gushterova | Robert Darnell | Peilin Ma | V. Yellapantula | Sagarika Pachhal | Glorymar Ibanez Sanchez | Irena Gushterova
[1] Simon C Watkins,et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.
[2] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[3] S. Chandarlapaty,et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition , 2016, Cancer cell.
[4] J. Toretsky,et al. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. , 1999, Cancer research.
[5] A. Viale,et al. Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas. , 2017, JCO precision oncology.
[6] Shadma Parveen,et al. Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206 , 2014, PloS one.
[7] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[8] M. Rubin,et al. MAGI3–AKT3 fusion in breast cancer amended , 2015, Nature.
[9] S. Nada,et al. p18/LAMTOR1: a late endosome/lysosome-specific anchor protein for the mTORC1/MAPK signaling pathway. , 2014, Methods in enzymology.
[10] A. Iafrate,et al. Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.
[11] Pang-Kuo Lo,et al. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination , 2011, Proceedings of the National Academy of Sciences.
[12] Geoffrey E. Hinton,et al. Visualizing Data using t-SNE , 2008 .
[13] S. Fulda,et al. Activation of Akt predicts poor outcome in neuroblastoma. , 2007, Cancer research.
[14] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[15] R. Purohit,et al. Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain , 2013, PloS one.
[16] A. Kral,et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .
[17] Juan Carlos Fernández,et al. Multiobjective evolutionary algorithms to identify highly autocorrelated areas: the case of spatial distribution in financially compromised farms , 2014, Ann. Oper. Res..
[18] Z. Weng,et al. PGBD5 promotes site-specific oncogenic mutations in human tumors , 2017, Nature Genetics.
[19] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[20] Chao Zhang,et al. Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.
[21] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[22] Somasekar Seshagiri,et al. Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers , 2012, Proceedings of the National Academy of Sciences.
[23] A. Milosavljevic,et al. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma , 2015, Proceedings of the National Academy of Sciences.
[24] J. Tabernero,et al. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors , 2014, Molecular Cancer Therapeutics.
[25] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[26] B. Taylor,et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[28] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[29] G. Thomas,et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.
[30] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[31] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[32] N. Socci,et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.
[33] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[34] H. Xiang,et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma , 2007, Modern Pathology.
[35] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[36] Sebastian Maurer-Stroh,et al. N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences. , 2002, Journal of molecular biology.
[37] F. Salvatore,et al. Rapid detection of mycoplasma in continuous cell lines using a selective biochemical test. , 2008, Leukemia research.
[38] Li Ding,et al. The Pediatric Cancer Genome Project , 2012, Nature Genetics.
[39] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[40] P. Cohen,et al. Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.
[41] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[42] Maristela L Onozato,et al. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. , 2017, Cancer discovery.
[43] M. Andjelkovic,et al. Phosphorylation and activation of p70s6k by PDK1. , 1998, Science.
[44] B. Johansson,et al. The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.
[45] C. Kumar,et al. AKT crystal structure and AKT-specific inhibitors , 2005, Oncogene.
[46] Sebastian Maurer-Stroh,et al. N-terminal N-myristoylation of proteins: prediction of substrate proteins from amino acid sequence. , 2002, Journal of molecular biology.
[47] V. Vacic,et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.
[48] Stuart J. Andrews,et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma , 2016, Genome Medicine.